Truvian Sciences

Truvian Sciences is commercializing the TruVerus™ system, which it claims is the world's first FDA-cleared multimodal automated benchtop analyzer, combining clinical chemistry, immunoassay, and hematology testing in a single, compact instrument. The company employs a staged FDA clearance strategy, having already secured clearances for a panel of routine tests including metabolic panels, liver enzymes, lipids, and a CBC with differential, with more assays under review. Truvian's value proposition targets decentralized care settings by eliminating sample send-outs, reducing blood volume requirements, and providing rapid results to enable timely clinical decisions.

The TruVerus™ automated benchtop analyzer, a multimodal platform integrating clinical chemistry, immunoassay, and hematology testing in a single, compact instrument using patented integration and proprietary dry reagent technology.

Truvian competes in the point-of-care diagnostics market against giants like Abbott (i-STAT, Afinion), Roche (cobas), and Siemens, as well as companies like Quest Diagnostics and Labcorp in the central lab space. Its differentiation is the unique multimodal integration in one benchtop device, a claim few, if any, competitors currently match for routine testing.